Loading...
XTAEBOLT
Market cap6mUSD
Dec 24, Last price  
475.20ILS
1D
-1.61%
1Q
13.36%
Jan 2017
-62.71%
IPO
-99.00%
Name

Biolight Life Sciences Ltd

Chart & Performance

D1W1MN
XTAE:BOLT chart
P/E
—
P/S
18,757.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.88%
Rev. gr., 5y
-49.76%
Revenues
118k
+87.30%
52,00082,000941,0001,391,0002,111,0001,209,0003,687,000297,00031,0003,00063,000118,000
Net income
-26m
L+231.59%
-13,356,000-18,837,000-23,102,000-19,259,000-21,824,000-17,260,00065,385,000-12,591,000-13,382,000382,000-7,847,000-26,020,000
CFO
-10m
L+0.39%
-19,460,000-26,225,000-26,987,000-24,037,000-26,942,000-25,318,000-22,390,000-15,357,000-11,395,000-10,026,000-9,540,000-9,577,000
Earnings
Apr 08, 2025

Profile

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.
URL
https://www.bio-light.co.il
IPO date
Dec 27, 2005
Employees
5
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
118
87.30%
63
2,000.00%
3
-90.32%
Cost of revenue
10,769
6,201
7,035
Unusual Expense (Income)
NOPBT
(10,651)
(6,138)
(7,032)
NOPBT Margin
Operating Taxes
(2,449)
(1,572)
Tax Rate
NOPAT
(10,651)
(3,689)
(5,460)
Net income
(26,020)
231.59%
(7,847)
-2,154.19%
382
-102.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,859
BB yield
-7.29%
Debt
Debt current
91
527
443
Long-term debt
91
527
443
Deferred revenue
783
543
Other long-term liabilities
836
Net debt
(27,833)
(47,213)
(58,396)
Cash flow
Cash from operating activities
(9,577)
(9,540)
(10,026)
CAPEX
(1,415)
(98)
(626)
Cash from investing activities
(1,952)
(10,550)
13,481
Cash from financing activities
3,255
(485)
915
FCF
(10,206)
(5,145)
12,655
Balance
Cash
8,643
16,379
33,467
Long term investments
19,372
31,888
25,815
Excess cash
28,009
48,264
59,282
Stockholders' equity
(220,478)
(196,771)
(189,005)
Invested Capital
251,706
251,773
251,408
ROIC
ROCE
EV
Common stock shares outstanding
4,644
4,586
4,586
Price
5.20
-21.40%
6.61
-42.70%
11.54
52.87%
Market cap
24,136
-20.40%
30,320
-42.70%
52,919
54.31%
EV
(3,172)
(16,369)
(4,762)
EBITDA
(10,077)
(5,550)
(6,500)
EV/EBITDA
0.31
2.95
0.73
Interest
66
22
Interest/NOPBT